EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Prospective Trial of Radiofrequency Catheter Ablation of High Dominant Frequencies After Pulmonary Vein Isolation in Non‐Paroxysmal Atrial Fibrillation (PAD‐AF Trial): A Multicenter, Randomized Clinical Trial

Koji Kumagai, Tomoaki Hasegawa, Daisuke Kutsuzawa, Yuichi Hanaki iD, Masahide Harada iD, Hitoshi Hachiya, Yuhi Hasebe, Kazuki Noda iD, Minoru Yambe, Hirohito Metoki iD, Kazutaka Aonuma

Journal of Cardiovascular Electrophysiology · 2026-07 · 37 (7) · 1410-1420

DOI: 10.1111/jce.70357 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 03.05.2026. Verfasst von Koji Kumagai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Tohoku Medical and Pharmaceutical University, Miyagi, Japan. Hauptthemen laut MEDLINE: Catheter Ablation, Atrial Fibrillation, Pulmonary Veins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Ministry of Education, Culture, Sports, Science, and Technology, Tokyo, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of dominant frequency (DF)–guided ablation after pulmonary vein isolation (PVI) in persistent atrial fibrillation (AF) remains uncertain. We evaluated the clinical and mechanistic impact of DF mapping in a multicenter randomized study. Methods and Results In this multicenter, prospective study, 103 patients were enrolled. Patients with high‐DF sites (≥ 7 Hz) were randomized 1:1 to PVI plus DF ablation (DF group, n = 32) or PVI alone (PVI group, n = 32). Patients without high‐DF sites (< 7 Hz, n = 39) underwent PVI only (non‐DF group; exploratory cohort). The primary endpoint was freedom from documented AF recurrence without antiarrhythmic drugs (AADs) at 12 months. AF‐free survival off AADs was 81.3% in the DF group versus 68.9% in the PVI group ( p = 0.228) at 12 months. Arrhythmia‐free survival with or without AADs was 78.1% versus 65.6% ( p = 0.263). The non‐DF group showed the most favorable outcomes (83.3%, p = 0.065 vs PVI group). No adverse events were associated with DF mapping or ablation. Multivariate analysis identified right atrial (RA) low‐voltage area extent (HR 1.031, 95% CI 1.005–1.058, p = 0.018) and LA diameter (HR 0.899, 95% CI 0.816–0.991, p = 0.032) as independent predictors of recurrence.

Conclusions

In this multicenter randomized trial, adjunctive DF‐guided ablation following PVI did not result in a statistically significant improvement in arrhythmia‐free survival compared with PVI alone. However, the absence of high‐DF sites was associated with favorable outcomes, and RA low‐voltage burden emerged as an independent predictor of recurrence, supporting the potential mechanistic value of DF mapping and highlighting the prognostic importance of right atrial structural remodeling. Trial Registration UMIN000042543.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Catheter AblationAtrial FibrillationPulmonary VeinsHumansFemaleProspective StudiesRecurrenceTime FactorsMiddle AgedTreatment OutcomeMaleAction PotentialsAnti-Arrhythmia AgentsRisk FactorsAgedProgression-Free SurvivalElectrophysiologic Techniques, CardiacHeart RateJapan

Stichwörter der Autor:innen

atrial fibrillationcatheter ablationdominant frequenciespulmonary vein isolation

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Tohoku Medical and Pharmaceutical University, Miyagi, Japan.
  • Division of Cardiology, Mito Saiseikai General Hospital, Ibaraki, Japan.
  • Division of Cardiology, Yamagata University Hospital, Yamagata, Japan.
  • Division of Cardiology, University of Tsukuba Hospital, Ibaraki, Japan.
  • Division of Cardiology, Fujita Health University, Aichi, Japan.
  • Division of Cardiology, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.

ORCID-Profile: Yuichi Hanaki, Masahide Harada, Kazuki Noda, Hirohito Metoki

Förderung

  • Japanese Ministry of Education, Culture, Sports, Science, and Technology, Tokyo, Japan

Zitieren

APA

Kumagai, K., Hasegawa, T., Kutsuzawa, D., Hanaki, Y., Harada, M., Hachiya, H., Hasebe, Y., Noda, K., Yambe, M., Metoki, H., & Aonuma, K. (2026). Prospective Trial of Radiofrequency Catheter Ablation of High Dominant Frequencies After Pulmonary Vein Isolation in Non‐Paroxysmal Atrial Fibrillation (PAD‐AF Trial): A Multicenter, Randomized Clinical Trial. Journal of Cardiovascular Electrophysiology, 37(7), 1410-1420. https://doi.org/10.1111/jce.70357

Vancouver

Kumagai K, Hasegawa T, Kutsuzawa D, Hanaki Y, Harada M, Hachiya H, et al. Prospective Trial of Radiofrequency Catheter Ablation of High Dominant Frequencies After Pulmonary Vein Isolation in Non‐Paroxysmal Atrial Fibrillation (PAD‐AF Trial): A Multicenter, Randomized Clinical Trial. Journal of Cardiovascular Electrophysiology. 2026;37(7):1410-1420. doi:10.1111/jce.70357

BibTeX
@article{Kumagai2026,
  author = {Kumagai, Koji and Hasegawa, Tomoaki and Kutsuzawa, Daisuke and Hanaki, Yuichi and Harada, Masahide and Hachiya, Hitoshi and Hasebe, Yuhi and Noda, Kazuki and Yambe, Minoru and Metoki, Hirohito and Aonuma, Kazutaka},
  title = {Prospective Trial of Radiofrequency Catheter Ablation of High Dominant Frequencies After Pulmonary Vein Isolation in Non‐Paroxysmal Atrial Fibrillation (PAD‐AF Trial): A Multicenter, Randomized Clinical Trial},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2026},
  volume = {37},
  number = {7},
  pages = {1410--1420},
  doi = {10.1111/jce.70357}
}
Kostenlos starten →